{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vistusertib", "query": { "intervention": "Vistusertib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T20:04:46.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02831257", "title": "AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurofibromatosis 2", "Meningioma" ], "interventions": [ { "name": "AZD2014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-08-31", "completion_date": "2020-10-01", "has_results": true, "last_update_posted_date": "2022-06-13", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02831257" }, { "nct_id": "NCT03071874", "title": "Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Meningioma" ], "interventions": [ { "name": "AZD2014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-10-17", "completion_date": "2024-07-25", "has_results": false, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071874" }, { "nct_id": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 528, "start_date": "2017-12-18", "completion_date": "2026-09-11", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 17, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334617" }, { "nct_id": "NCT03366103", "title": "Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Recurrent Lung Small Cell Carcinoma", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7", "Stage IIIA Lung Small Cell Carcinoma AJCC v7", "Stage IIIB Lung Small Cell Carcinoma AJCC v7", "Stage IV Lung Small Cell Carcinoma AJCC v7", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Navitoclax", "type": "BIOLOGICAL" }, { "name": "Vistusertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-03-20", "completion_date": "2022-09-21", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 14, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03366103" }, { "nct_id": "NCT03205046", "title": "A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "DLBCL", "Richter Syndrome" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" }, { "name": "vistusertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 25, "start_date": "2017-06-29", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2021-01-06", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 7, "location_summary": "Fairway, Kansas • Bethesda, Maryland • Rochester, Minnesota + 4 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03205046" }, { "nct_id": "NCT02599714", "title": "Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced and Metastatic Breast Cancer" ], "interventions": [ { "name": "AZD2014", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 54, "start_date": "2015-12-07", "completion_date": "2023-11-23", "has_results": false, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 5, "location_summary": "Encinitas, California • Sarasota, Florida • Detroit, Michigan + 2 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02599714" }, { "nct_id": "NCT02208375", "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Endometrial Adenocarcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "High Grade Ovarian Serous Adenocarcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vistusertib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 159, "start_date": "2014-11-11", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02208375" }, { "nct_id": "NCT01597388", "title": "AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Metastatic Breast Cancer" ], "interventions": [ { "name": "AZD2014", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 99, "start_date": "2012-05-08", "completion_date": "2026-01-13", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 5, "location_summary": "Sarasota, Florida • Detroit, Michigan • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01597388" }, { "nct_id": "NCT02546661", "title": "Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "AZD4547", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "AZD1775", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "AZD9150", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 117, "start_date": "2016-12-28", "completion_date": "2026-01-30", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-09-02T20:04:46.375Z", "location_count": 8, "location_summary": "Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546661" } ] }